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Abstract To unravel the mechanism of interleukin-13 (IL-13)-
speci¢c functions, we sought to identify IL-13 receptor (IL-13R)
binding molecules. A novel human IL-13RK1 binding protein
(IL13RBP1) has been identi¢ed using yeast tri-hybrid system,
which was found to encode the same protein as MIP-T3 (micro-
tubule interacting protein that associates with tumor necrosis
factor (TNF) receptor associating factor-3 (TRAF3)). It con-
stitutively associates with IL-13RK1 and suppresses IL-4/13-in-
duced signal transducer and activator of transcription-6
(STAT6) phosphorylation. IL-13-induced STAT6 activation
was also inhibited as determined by dual luciferase assay and
electrophoretic mobility shift assay (EMSA). These results sug-
gest that MIP-T3 is a novel inhibitor of IL-13 signaling and
may be a useful molecule in ameliorating various conditions in
which IL-13 plays a central role.
. 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Interleukin (IL)-13 is a pleiotropic immune regulatory cy-
tokine that shares many structural and functional character-
istics with IL-4 [1]. Despite their similarities, not all biological
activities are mutual and overlapping due to di¡erential ex-
pression of IL-4 and IL-13 receptor (IL-13R) complexes on
various cell types. IL-13 has been shown to be necessary and
su⁄cient for induction of asthma. In mouse models of allergic
asthma, IL-13 blockade prevented allergen-induced airway in-
£ammation while IL-13 delivery to the airway caused airway
hyperresponsiveness (AHR), mucus production and eosino-
philia [2^4]. IL-13 knockout mice failed to develop allergen-
induced AHR; however, AHR was restored in IL-13(3/3)
mice by the administration of recombinant IL-13 [5]. It has
also been shown that IL-13 is more important than IL-4 as an
inducer of the signal transducer and activator of transcrip-
tion-6 (STAT6) in stimulating parasite expulsion [6]. In addi-
tion, IL-13 but not IL-4 is found to be an autocrine growth
factor for Reed^Sternberg cells in Hodgkin lymphoma [7,8].
IL-13 signals were mediated mainly through Janus kinase
(JAK)-STAT pathway and insulin receptor substrate (IRS)-1/
2-phosphatidylinositol 3P-kinase (PI3k) pathway by using a
complex of IL-4R and IL-13RK1 [9^11]. But these could not
o¡er su⁄cient explanation as to why IL-13 possesses distinct
roles from IL-4. However, STAT6 has already been shown to
be indispensable for IL-13-speci¢c biological properties
[12,13]. Therefore, identifying mechanisms of STAT6 regula-
tion should be useful to de¢ne the distinct roles of IL-13.
In this study we have identi¢ed a novel IL-13R binding
molecule by using yeast tri-hybrid system. The protein was
termed as IL13RBP1 (IL-13RK1 binding protein-1), which
can constitutively associate with IL-13RK1 chain, but not
with IL-4RK and IL-2RQ. Interestingly, IL13RBP1 was found
later to encode the same protein as MIP-T3 (microtubule
interacting protein that associates with tumor necrosis factor
(TNF) receptor associating factor-3 (TRAF3)), which can in-
teract with microtubules and TRAF3 protein [14]. In our
study, MIP-T3 was shown to suppress STAT6 tyrosine phos-
phorylation in response to IL-4/13 stimulation. However,
MIP-T3 inhibits DNA binding activity and transcriptional
activity in response to IL-13 but not to IL-4 stimulation.
The role of MIP-T3 in IL-13 signals and its association with
TRAF3 and microtubules suggest that it may work as a cross
point between IL-13 and CD40 signaling pathway.
2. Materials and methods
2.1. Cell lines, cytokines and antibodies
THP-1 cells were cultured in RPMI-1640, 293T cells were cultured
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) and COS-7 cells
were cultured in minimal essential medium (MEM) containing 10%
fetal bovine serum. Recombinant human IL-4 (hIL-4) and human IL-
0014-5793 / 03 / $22.00 I 2003 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
doi:10.1016/S0014-5793(03)00860-3
*Corresponding author. Fax: (81)-95-819 2898.
E-mail address: muratat@net.nagasaki-u.ac.jp (T. Murata).
Abbreviations: AHR, airway hyperresponsiveness; EMSA, electro-
phoretic mobility shift assay; IL-13R, interleukin-13 receptor; JAK,
Janus kinase; MIP-T3, microtubule interacting protein that associates
with tumor necrosis factor receptor associating factor-3; STAT, signal
transducer and activator of transcription; TRAF, tumor necrosis fac-
tor receptor associating factor
FEBS 27559 13-8-03
FEBS 27559 FEBS Letters 550 (2003) 139^143
13 (hIL-13) were purchased from PEPRO TECH EC Ltd (UK). Anti-
c-myc (9E10), Omni-probe (M-21) (anti-His), anti-STAT6 (S-20), anti-
IL-4RK (C-20) and anti-IL-2RQ (N-20) antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Biotin-con-
jugated anti-phosphotyrosine (4G10) and streptavidin-horseradish
peroxidase (HRP) were from Upstate Biotechnology (Lake Placid,
NY, USA).
2.2. Yeast tri-hybrid cloning
pBTM-JH-IL-13RK1 (cytoplasmic domain) was constructed and
used as a bait to screen human fetal liver cDNA library (Clontech,
USA) [15]. Positive yeast clones were selected by prototrophy for
histidine or expression of L-galactosidase, and then subjected to se-
quence analysis to search for novel IL-13RK1 binding proteins. Asso-
ciation between IL-13RK1 and new proteins was con¢rmed in yeast
two-hybrid system: Plasmid containing target gene and pAS21-IL-
13RK1 (cytoplasmic domain) were transformed into CG1945 strain.
Histidine and L-galactosidase expression was determined to detect the
association. The whole length of cDNA was cloned from human testis
cDNA library (Clontech) by using 5P-rapid ampli¢cation of comple-
mentary deoxyribonucleic acid ends-polymerase chain reaction
(RACE-PCR).
2.3. Immunoprecipitation and Western blot
Cells were transfected by using Lipofectamine 2000 (Invitrogen,
USA) according to the manufacturer’s instruction. After transfection,
cells were harvested and stimulated with hIL-4 or hIL-13 at 37‡C for
15 min. Cells were lysed in lysis bu¡er containing 50 mM Tris^HCl
(pH 7.4), 300 mM NaCl, 0.1% NP-40, 5 Wg/ml leupeptin, 10 Wg/ml
aprotinin, 10 Wg/ml pepstatin A, and 1 mM phenylmethylsulfonyl
£uoride (PMSF). Cell lysates were incubated with antibody-conju-
gated protein G/A-Sepharose 4B (Sigma Aldrich, USA) overnight at
4‡C. Immunoprecipitated proteins were separated on sodium dodecyl
sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and trans-
ferred to Immobilon polyvinylidene di£uoride (PVDF) transfer mem-
brane (Millipore, Japan). Immunoblots were incubated with antibod-
ies as required. Signal was detected by using enhanced chemilumi-
nescence (ECL) Western detection reagent and exposed to Hyper-
¢lm1 ECL (Amersham Pharmacia Biotech, UK).
To detect STAT6 tyrosine phosphorylation, cells were harvested in
lysis bu¡er containing phosphatase inhibitor (1 mM Na3VO4, 25 mM
NaF, 10 mM Na-pyrophosphate and 1 mM ethylenediamine tetra-
acetic acid (EDTA)). Immunoblot was reacted with diluted biotin-
4G10 for 4 h and HRP-conjugated streptavidin for 30 min at room
temperature. Finally ECL detection was performed and images
were recorded by using Luminescent Image Analyzer LAS1000 plus
(FUJIFILM, Japan).
2.4. Dual luciferase assay
TPU474 reporter gene was used for dual luciferase assay to deter-
mine STAT6 transcriptional activity. It contains four copies of indi-
vidual oligonucleotide (C/EBP-N4) and a truncated thymidine kinase
promoter (TK) [16]. N4 is a STAT6-speci¢c binding site and TK
drives expression of luciferase reporter gene (LUC). TPU474 and
pSRHisA-MIP-T3 were transfected to COS-7 cells by using Lipofect-
amine 2000. pRL-TK vector (Promega, USA) expressing Sea pansy
luciferase was co-transfected with every sample as internal control.
After 24 h, cells were stimulated with recombinant hIL-4 (50 ng/ml)
or hIL-13 (100 ng/ml) at 37‡C for 6 h. Luciferase activity was mea-
sured by using Pica Gene Dual luciferase kit (Toyo Ink, Tokyo, Ja-
pan). Every sample was done in duplicate and each experiment was
repeated twice. Expression of MIP-T3 in every sample was determined
by immunoblotting analysis using Omni-probe.
2.5. Electrophoretic mobility shift assay (EMSA)
Plasmid DNA was transfected into semicon£uent cells using Gene-
PORTER transfection reagent (Gene Therapy Systems, USA) ac-
cording to the manufacturer’s instructions. 2 days later, cells were
Fig. 1. Speci¢c association between MIP-T3 and IL-13RK1. A: Plasmids encoding IL-13RK1 (10 Wg) and MIP-T3 (15 Wg) were transfected to
293T cells in a 90 mm dish by using Lipofectamine 2000. 24 h later, cells were stimulated with or without hIL-4 or hIL-13 at 37‡C for 15 min.
Cell lysates were immunoprecipitated (IP) with anti-c-myc antibody and immunoblotted (IB) with Omni-probe (top panel). Expression levels of
MIP-T3 (middle panel) and IL-13RK1 (lower panel) in total cell lysates were determined by immunoblotting with Omni-probe or anti-c-myc.
Arrow indicates position of co-precipitated MIP-T3 protein. B: 293T cells were transfected with plasmids encoding various receptors (10 Wg)
and MIP-T3 (15 Wg). Cell lysates were immunoprecipitated with Omni-probe and immunoblotted with anti-c-myc, anti-IL-4RK (C-20), or anti-
IL-2RQ (N-20) antibody to detect co-precipitated receptors (top panel). Expression levels of receptors (middle panel) and MIP-T3 (lower panel)
in total cell lysates were determined by immunoblotting with corresponding antibodies. * indicates co-precipitated IL-13RK1 protein. Arrows in-
dicate positions of receptors.
FEBS 27559 13-8-03
Y. Niu et al./FEBS Letters 550 (2003) 139^143140
harvested and stimulated with hIL-4 (50 ng/ml) or hIL-13 (250 ng/ml)
for 10 min. Cells were then washed with cold phosphate-bu¡ered sa-
line (PBS) and solubilized with cold whole cell extraction bu¡er (10
Wg/ml leupeptin, 10 Wg/ml pepstatin A, 10 Wg/ml aprotinin, 20 mM
HEPES (pH 7.0), 10 mM KCl, 300 mM NaCl, 0.5 mM dithiothreitol
(DTT), 0.1% NP-40, 1 mM PMSF, 1 mM Na3VO4, and 20% glycer-
ol). 50 Wg of sample proteins were incubated in 20 Wl of binding bu¡er
(10 mM Tris^HCl (pH 7.5), 50 mM NaCl, 0.5 mM DTT, 10% glyc-
erol, 0.05% NP-40, and 0.05 mg/ml poly(dI-dC)2) for 20 min at room
temperature with 1 ng of 32P-labeled double stranded oligonucleotide
probe SBE-1 [10]. Samples were applied to 4% non-reducing polyac-
rylamide gel and run at 150 V for 2.5 h. Gels were dried for 2 h and
autoradiographed.
3. Results
3.1. Cloning of IL13RBP1 using yeast tri-hybrid system
To clarify the molecular and cellular events involved in IL-
13-speci¢c signaling pathways, we searched for novel IL-
13RK1 binding proteins by using yeast tri-hybrid system.
Among the positive clones obtained, one fragment encoding
125 amino acids was found to associate with the cytoplasmic
domain of IL-13RK1 independent of tyrosine phosphorylation
in yeast two- and tri-hybrid system.
By using this fragment as probe, the entire gene was cloned
from human testis cDNA library, which has a whole length of
2568 bp and encodes a protein of 691 amino acids. It was
named IL13RBP1 and submitted to GenBank (GenBank Ac-
cession Number AF242456). Coincidentally, another protein
named MIP-T3 (GenBank Accession Number NM_015650)
was found to be the same one as IL13RBP1. MIP-T3 was
reported to constitutively associate with TRAF3 and to inter-
act with microtubule, while in our studies it was cloned as an
IL-13RK1 binding protein.
3.2. Interaction of MIP-T3 with IL-13RK1 in mammalian cells
To con¢rm the association between MIP-T3 and IL-13RK1
in mammalian cells, pSRHisA-MIP-T3 was constructed and
transfected to 293T cells with pME-IL-13RK1-c-myc [10]. As-
sociation was detected by immunoprecipitation. MIP-T3 can
be co-precipitated with IL-13RK1 only when both proteins
were expressed indicating their speci¢c association (Fig. 1A,
top panel, lane 1). In addition, the e¡ects of hIL-4/13 on the
association between MIP-T3 and IL-13RK1 were investigated.
In Fig. 1A (lanes 4, 5), band intensities of co-precipitated
MIP-T3 did not change before and after hIL-4/13 stimulation.
Therefore, the association between MIP-T3 and IL-13RK1
was not a¡ected by IL-4/13.
Besides IL-13RK1, we also checked whether MIP-T3 asso-
ciates with IL-4RK or IL-2RQ. Plasmids encoding di¡erent
receptors were transfected into 293T cells with pSRHisA-
MIP-T3. MIP-T3 protein was immunoprecipitated with
Omni-probe and co-precipitated receptors were detected
with related antibodies. Results in Fig. 1B showed that only
IL-13RK1 (lane 6) could be pulled down with MIP-T3, while
IL-4RK (lane 8) and IL-2RQ (lane 9) could not.
The above results suggest that MIP-T3 may be a speci¢c
IL-13RK1 binding protein and its association is not a¡ected
by hIL-4 or hIL-13.
3.3. Suppression of hIL-4/13-induced STAT6 tyrosine
phosphorylation by MIP-T3
To gain an insight into functional importance of MIP-T3
association with IL-13RK1, we studied whether STAT6 phos-
phorylation was a¡ected by MIP-T3. COS-7 cell line was used
as it expresses all necessary IL-4/13 signal molecules [17]. As
shown in Fig. 2A, after introduction of MIP-T3, STAT6
phosphorylation was partially inhibited in response to hIL-4
and hIL-13 stimulation, but MIP-T3 suppression of IL-4-in-
duced STAT6 phosphorylation (lanes 3, 4) was weaker than
that of hIL-13 (lanes 5, 6).
To con¢rm the above results, we introduced various
amounts of pSRHisA-MIP-T3 to COS-7 cells and detected
STAT6 phosphorylation. As shown in Fig. 2B, with increas-
ing amounts of transfected plasmid, STAT6 phosphorylation
in response to hIL-13 was suppressed gradually. IL-4-induced
STAT6 phosphorylation was determined in the same experi-
ment. STAT6 phosphorylation was suppressed by MIP-T3,
but the e¡ect was modest compared to that of IL-13 (Fig.
Fig. 2. Suppression of STAT6 phosphorylation by MIP-T3 in re-
sponse to hIL-4/13. A: COS-7 cells in a 90 mm dish were trans-
fected with 6 Wg of pSRHisA-MIP-T3 or pSRHisA by using Lipo-
fectamine 2000. After 24 h, cells were stimulated with or without
hIL-4 (50 ng/ml) and hIL-13 (250 ng/ml) at 37‡C for 15 min. Cell
lysates were immunoprecipitated (IP) with anti-STAT6 antibody and
immunoblotted (IB) with biotin-4G10 (top panel). Immunoblot was
stripped and reprobed with anti-STAT6 antibody to check the
amount of immunoprecipitated STAT6 protein (middle panel). Ex-
pression level of MIP-T3 in whole cell lysates was determined by
immunoblotting (IB) with Omni-probe (lower panel). B, C: COS-7
cells were transfected with various amounts of pSRHisA-MIP-T3 or
pSRHisA. After 24 h, cells were harvested and stimulated with hIL-
13 (B) or hIL-4 (C) at 37‡C for 15 min. STAT6 phosphorylation
and MIP-T3 expression level were determined as described in A.
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2C). Therefore, MIP-T3 can suppress STAT6 tyrosine phos-
phorylation especially in response to hIL-13.
3.4. Suppression of STAT6 transcriptional activity by MIP-T3
After demonstrating the inhibitory e¡ect of MIP-T3 on
STAT6 phosphorylation, STAT6 transcriptional activity was
determined by dual luciferase assay using COS-7 cells. Upon
hIL-4 or hIL-13 stimulation, 4^5-folds induction of luciferase
activity was observed in control cells. However, after trans-
fection of pSRHisA-MIP-T3, folds induction in response to
hIL-13 decreased while there was no obvious change in hIL-4-
stimulated cells (Fig. 3A), although expression levels of MIP-
T3 were proved to be equal among all samples (Fig. 3B). The
decreased folds induction demonstrated that STAT6 tran-
scriptional activity in response to hIL-13 stimulation can be
suppressed by MIP-T3.
3.5. Inhibition of activated STAT6 DNA binding activity by
MIP-T3
Besides dual luciferase assay, EMSA was performed to de-
termine the e¡ect of MIP-T3 on STAT6 DNA binding activity
by using THP-1 cells. SBE-1 probe was used for binding as-
say, which speci¢cally bound to STAT6 protein as shown in
the right panel of Fig. 4A. When cells were introduced with
MIP-T3 gene and stimulated with hIL-13, intensity of STAT6
band was lowered to nearly 30% of that in control samples
(Fig. 4A, lanes 2, 4). The e¡ect of MIP-T3 on STAT6 in
response to hIL-4 was also examined; however, there was
no change before and after introduction of MIP-T3 (Fig.
4B, lanes 6, 8). In addition, cells were transfected with di¡er-
ent amounts of pSRHisA-MIP-T3 plasmid and stimulated
with hIL-13. We found that 6 Wg of MIP-T3 plasmid was
already enough to suppress STAT6 DNA binding activity in
THP-1 cells (Fig. 4C). These results con¢rmed the inhibitory
e¡ect of MIP-T3 on IL-13-induced STAT6 DNA binding ac-
tivity.
4. Discussion
We have identi¢ed a new IL-13RK1 binding protein
(IL13RBP1) by using yeast tri-hybrid system and found that
IL13RBP1 is the same protein as MIP-T3, which also inter-
acts with TRAF3 and microtubules. Besides the association,
we found that transient expression of MIP-T3 partially inhib-
ited IL-13-induced STAT6 phosphorylation, DNA binding
activity and transcriptional activity.
To clone IL-13RK1 binding proteins, yeast tri-hybrid sys-
tem was used because tyrosine phosphorylation was widely
utilized for cytokine signaling. However, MIP-T3 was found
to constitutively associate with IL-13RK1 independent of ty-
rosine phosphorylation, which is proven in both yeast system
(data not shown) and mammalian cells (Fig. 1A). Besides IL-
13RK1, IL-4RK is also utilized for IL-4/13 signaling and IL-
2RQ is utilized for IL-4 signaling, but they do not associate
with MIP-T3 (Fig. 1B). Thus MIP-T3 may be a speci¢c IL-
13RK1 binding protein.
We have investigated the role of MIP-T3 in IL-13 signals.
STAT6 has been shown to be indispensable for IL-13-speci¢c
Fig. 3. E¡ects of MIP-T3 on STAT6 transcriptional activity in re-
sponse to hIL-4/13 stimulation. A: COS-7 cells in a 12-well plate
were transfected with 0.4 Wg of TPU474, 1.6 Wg of pSRHisA-MIP-
T3 (or pSRHisA) and 0.02 Wg of pRL-TK per well by using Lipo-
fectamine 2000. After 24 h, cells were stimulated with hIL-4 (50 ng/
ml) or hIL-13 (100 ng/ml) at 37‡C for 6 h. Cells were harvested and
measured for luciferase activity. Luciferase activity was normalized
by Sea pansy activity to eliminate the in£uence of transfection e⁄-
ciency and cell viability. Fold induction was calculated as the ratio
of relative luminescence units (RLU) of stimulated cells to that of
non-stimulated cells. Values are expressed as means of four indepen-
dent experiments. *P6 0.05, versus control. B: Expression level of
MIP-T3 was determined by loading an equal amount of cell lysates
to SDS^PAGE and immunoblotting with Omni-probe.
Fig. 4. E¡ects of MIP-T3 on activated STAT6 DNA binding activ-
ity in response to hIL-4/13 stimulation. A, B: THP-1 cells in a 90
mm dish were transfected with 12 Wg of pSRHisA-MIP-T3 or
pSRHisA. C: THP-1 cells were transfected with various amounts of
pSRHisA-MIP-T3 (0^12 Wg). 2 days later, cells were incubated with
hIL-13 (A, C) (250 ng/ml) or hIL-4 (B) (50 ng/ml) for 10 min, solu-
bilized with cold whole cell extraction bu¡er, and 50 Wg of sample
protein was incubated with 1 ng of 32P-labeled SBE-1 probe (or
with non-radiolabeled SBE-1 probe, A, right panel) in binding bu¡-
er for 20 min. DNA^protein interaction was analyzed by PAGE
analysis. Arrows indicate STAT6 positions.
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biological functions [18,19] but the detailed mechanism is still
unknown. We studied the in£uence of MIP-T3 on STAT6
using transient expression system and found that STAT6
phosphorylation was suppressed by MIP-T3 (Fig. 2). Interest-
ingly, the e¡ect of MIP-T3 on hIL-13-induced STAT6 phos-
phorylation was stronger than that of hIL-4.
The e¡ect of MIP-T3 on hIL-4/13-induced STAT6 tran-
scriptional activity was also examined (Fig. 3). Corresponding
to inhibited STAT6 phosphorylation in response to hIL-13
stimulation, STAT6 transcriptional activity was suppressed
by MIP-T3. But MIP-T3 did not inhibit STAT6 activation
in response to hIL-4. This result was further con¢rmed in
EMSA (Fig. 4), in which MIP-T3 only suppressed STAT6
DNA binding activity in response to hIL-13, but not hIL-4.
These results suggest that MIP-T3 may selectively inhibit IL-
13 signaling.
Although we have cleared that MIP-T3 inhibits IL-13-in-
duced STAT6 phosphorylation and activation, its mechanism
remains unclear. No direct association was detected between
MIP-T3 and STAT6 protein (data not shown). Suppressor of
cytokine signaling (SOCS) proteins have been shown to be
important inhibitors of JAK-STAT pathway [20]. SOCS1
and SOCS5 can suppress IL-4-induced STAT6 activation.
SOCS1 directly binds to the activation loop of JAK through
SH2 domain thereby inhibiting STAT6 activation [21]. SOCS5
protein negatively regulates IL-4-induced STAT6 activation
and Th2 di¡erentiation through direct interaction with IL-
4R, which is also independent of receptor tyrosine phosphor-
ylation [22]. There is a possibility that interaction of MIP-T3
to IL-13RK1 may interfere with formation of receptor com-
plex or docking of STAT6 protein to receptor.
We have also examined the e¡ect of cytokine stimulation on
MIP-T3-TRAF3 association, which is proven to be in no
relation with IL-4/13 (data not shown). As reported by Ling
et al., upon CD40 ligand stimulation in 293.CD40 cells,
TRAF3 dissociates from MIP-T3 and is recruited to CD40
receptor [14]. But as CD40 receptor binding protein, the role
of TRAF3 in CD40 signaling has not been well de¢ned. As-
sociation of MIP-T3 to IL-13RK1 may o¡er a clue to study
the role of TRAF3 in CD40 signaling and it may also help
determine the relationship between IL-13 and CD40 signaling
pathway.
In summary, we have identi¢ed a new IL-13RK1 binding
protein, which is found to have inhibitory e¡ects on IL-13
signals through STAT6. This study would help to elucidate
a novel regulation mechanism of IL-13 signaling pathway.
Further studies will identify a novel inhibitor of IL-13 signal-
ing, which may be useful in ameliorating various IL-13-depen-
dent conditions including allergies, pulmonary asthma, para-
sitic infections and cancer in which IL-13 plays a central role.
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